Rabbit Nicotinic Acetylcholine Receptor alpha 4 Polyclonal Antibody | anti-Chrna4 antibody

Nicotinic Acetylcholine Receptor alpha 4 (cholinergic receptor, nicotinic, alpha 4 Precursor) (FITC)

Cat. Num. AAA6490036

• Gene Names: Chrna4; NARAC
• Reactivity: Rat, Human, Mouse
• Applications: Western Blot
• Purity: Purified by Immunoaffinity chromatography.
• Synonyms: Nicotinic Acetylcholine Receptor alpha 4; Polyclonal Antibody; Nicotinic Acetylcholine Receptor alpha 4 (cholinergic receptor; nicotinic; alpha 4 Precursor) (FITC); anti-Chrna4 antibody

• Host: Rabbit
• Reactivity: Rat, Human, Mouse
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes rat Nicotinic Acetylcholine Receptor a4. Species Crossreactivity: mouse, human.
• Purity/Purification: Purified by Immunoaffinity chromatography.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with Fluorescein Isothiocyanate (FITC).
• Sequence Length: 630

• Applicable Applications for anti-Chrna4 antibody: Western Blot (WB)
• Application Notes: WB: 1:1000; Applications are based on unconjugated antibody.
• Immunogen: Synthetic peptide selected from residues within the Nicotinic Acetylcholine Receptor a4. Epitope: Extracellular Domain
• Conjugate: FITC
• Positive Control: Rat e16 brain lysate
• Note: Preservative Free
• Preparation and Storage: May be stored at 4 degree C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Western Blot (WB)

(Western Blot Analysis: Representative lot data. Rat e16 Brain lysate was resolved by electrophoresis, transferred to PVDF and probed with N2563-01. Proteins were visualized using a donkey anti-rabbit secondary antibody conjugated to HRP and a chemiluminescence detection system. Arrow indicates Nicotinic Acetylcholine Receptor a4 (~55kD).)

Product Categories/Family for anti-Chrna4 antibody

Antibodies; Receptors; Cholinergic

NCBI and Uniprot Product Information

• NCBI GI #: 14149758
• NCBI GeneID: 25590
• NCBI Accession #: NP_077330
• NCBI GenBank Nucleotide #: NP_077330.1
• UniProt Accession #: P02708; P09483
• Molecular Weight: 55
• NCBI Official Full Name: neuronal acetylcholine receptor subunit alpha-4
• NCBI Official Synonym Full Names: cholinergic receptor nicotinic alpha 4 subunit
• NCBI Official Symbol: Chrna4
• NCBI Official Synonym Symbols: NARAC
• NCBI Protein Information: neuronal acetylcholine receptor subunit alpha-4
• UniProt Protein Name: Acetylcholine receptor subunit alpha
• Protein Family: Neuronal acetylcholine receptor
• UniProt Gene Name: CHRNA1
• UniProt Synonym Gene Names: ACHRA; CHNRA
• UniProt Entry Name: ACHA_HUMAN

NCBI Description

nicotinic acetylcholine receptor subunit responsible for binding calcium sensor protein visinin-like protein-1 (Vilip1), which modulates acetylcholine receptor expression and sensitivity [RGD, Feb 2006]

Uniprot Description

nAChRA1: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in CHRNA1 are a cause of multiple pterygium syndrome lethal type (MUPSL). Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent. The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs. Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS). SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes. Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS). FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha- 1/CHRNA1 sub-subfamily. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Receptor, misc.; Membrane protein, integral; Membrane protein, multi-pass; Channel, ligand-gated; Channel, cation

Chromosomal Location of Human Ortholog: 2q31.1

Cellular Component: nicotinic acetylcholine-gated receptor-channel complex; postsynaptic membrane; cell surface; plasma membrane; neuromuscular junction; cell junction

Molecular Function: acetylcholine receptor activity; ion channel activity; acetylcholine binding; nicotinic acetylcholine-activated cation-selective channel activity

Biological Process: muscle maintenance; skeletal muscle contraction; synaptic transmission; regulation of membrane potential; transport; neuromuscular process; generation of action potential; neuromuscular synaptic transmission; skeletal muscle growth; musculoskeletal movement; signal transduction; neuromuscular junction development

Disease: Myasthenic Syndrome, Congenital, Fast-channel; Myasthenic Syndrome, Congenital, Slow-channel; Multiple Pterygium Syndrome, Lethal Type